Event Media Board
A Message from the Co-Chairs of the FDA-Duke Global Regulatory Workshop
Welcome to this workshop!Cancer remains a serious global health threat. Oncology drug development has continued to lead other therapeutic areas in addressing the highly unmet medical needs of the cancer patients and their treatment, attested by ever-increasing numbers of global oncology clinical trials. Therefore, speeding up the development and making drugs available as rapidly as […]
Challenges with Novel Clinical Trial Designs: Master Protocols.
As seen on https://www.ncbi.nlm.nih.gov/pubmed/30696689 Cecchini M1, Rubin EH2, Blumenthal GM3, Ayalew K4, Burris HA5, Russell-Einhorn M6, Dillon H7, Lyerly HK8, Reaman GH9, Boerner S10, LoRusso PM10. The 2018 Accelerating Anticancer Agent Development (AAADV) Workshop assembled a panel of experts for an in-depth discussion session to present Challenges with Novel Clinical Trial Designs. This panel offered assessments of the challenges faced by industry, the Food and […]
First Regional Workshop Offered
First Regional Workshop Offered
FDA talks with AAADV Workshop
FDA talks with AAADV Workshop
AAADV Workshop 2016, Renzo Canetta
https://youtu.be/6Ut__0gUGxU AAADV Workshop 2016, Renzo Canetta
AAADV Workshop 2016, Gregory Reaman
AAADV Workshop 2016, Gregory Reaman Info Linkedin Link
AAADV Workshop 2016, Julie Bullock
Director of Clinical Pharmacology for d3 Medicine and Workshop planning committee member Julie Bullock explains how the unusual opportunity to interact informally with FDA officials involved in the drug approval process is an important opportunity for AAADV Workshop participants.
AAADV Workshop 2016, Tatiana Prowell
AAADV Workshop Published by Lori Wile · May 4 at 12:53pm · .. U.S. FDA’s Breast Cancer Scientific Lead and Workshop planning committee member Tatiana Prowell talks about AAADV’s goals and purpose at opening day of the 2016 Workshop.
AAADV Workshop 2016, Kim Lyerly
https://youtu.be/0ODYswwVDz0AAADV Workshop Chair Kim Lyerly on why the Workshop is unique: “It’s an open discussion with all the stakeholders in the drug development process on how to improve the whole process and make it better.”